RBD4059

Phase 2Small molecule

RRibocure Pharmaceuticals AB

RBD4059 is one of 46 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Coronary Artery DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

117 competitors in Coronary Artery Disease

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

15 2

Brilinta

AstraZeneca

Approved

13 3

Crestor

AstraZeneca

Approved

6 4

Ozempic

Novo Nordisk

Approved

2 5

Niacor

AbbVie

Approved

2 6

Effient

CCosette Pharmaceuticals, Inc.

Approved

8 7

Glucophage

EMD Serono

Approved

5 8

Ranexa

MMenarini International Operations Luxembourg SA

Approved

1 9

Cardizem

BBausch Health Americas, Inc.

Approved

1 10

Aggrastat

MMedicure

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Coronary Artery Disease1 trial

A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease

Active, not recruiting·RRibocure Pharmaceuticals AB·Phase 2·NCT06717074·30 enrolled

Unspecified1 trial

A Randomized, Single-blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD4059 in Healthy Subjects

Completed·SSuzhou Ribo Life Science Co. Ltd.·Phase 1·NCT05653037·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RBD4059. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RBD4059 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RBD4059. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ribocure Pharmaceuticals AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRibocure Pharmaceuticals AB

RBD4059

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Coronary Artery Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News